Neurology Clinical Trials Market Size, Share & Trends Analysis growing at a CAGR of 6.39% from 2025 to 2030

Besides, the rising number of diseases has increased the demand for neurology therapeutics. In addition, research & development (R&D) activities are enhancing core competencies, further fueling the growth. Moreover, the economic benefit of outsourcing compared to conducting an in-house study is also expected to propel market demand over the forecast period. The rising prevalence of Alzheimer’s disease, epilepsy, and stroke is significantly contributing to the market growth. Growing aging populations in developing and developed countries have led to a surge in age-related neurological disorders.

Furthermore, according to the research article published by IQVIA in March 2024, the CNS drugs accounted for 14% of the total industry pipeline drugs and are the second largest therapeutic area in active clinical trials. This strong development activity by market players demonstrates the significant investment and research and development activities in the market. For instance, in March 2025, Novartis announced to present its strength in its neuroscience portfolio at the American Academy of Neurology. This will include seven-year-old disability progression and safety outcomes from the ALITHIOS open-label extension study of Kesimpta (ofatumumab) in patients with relapsing multiple sclerosis (RMS). Moreover, the company aims to highlight its updates on pipeline candidates such as remibrutinib and iptacopan, underscoring its commitment to advancing innovative treatments for neurological disorders. Thus, constant development by market players and their growing product pipelines to meet the growing demand for patients would further contribute to market growth.